On 11 September 2026, ALI HEALTH (00241.HK) announced that with effect from the close of business that day, Mr. Yu Yong was appointed executive director, chairman, CEO, chairman of the nomination committee and authorised representative, while Mr. Shen Difan resigned from those roles but remains an executive director; Mr. Yu, aged 50, joined the Alibaba Group in March 2005 and served as CEO and president of 1688.com from February 2022 to September 2026, with his executive director appointment running for one year from 11 September 2026, and the company disclosed that combining the chairman and CEO roles deviates from Rule C.2.1 of the Corporate Governance Code.
On 11 September 2026, CHUNLI MEDICAL (01858.HK) announced that Mr. Yip Pui Sum, its company secretary, authorised representative under Rule 3.05 of the Listing Rules and process agent under Part 16 of the Companies Ordinance and Rule 19A.13(2), was confirmed to have passed away on 10 September 2026 after more than ten years of service; with no company secretary or process agent and only one authorised representative remaining, the company will not comply with Rules 3.28, 3.05 and 19A.13(2) and sections 474 and Part 16 of the Companies Ordinance, and the board will identify suitable candidates as soon as practicable.
On 11 September 2026, S HARBOURHOLD (01663.HK) announced that chairman and substantial shareholder Mr. Wang Linbing purchased an aggregate of 7,684,000 ordinary shares on the open market at an average price of approximately HKD 0.062 per share and a maximum price of HKD 0.063; Mr. Wang is the husband of substantial shareholder Ms. Chen Xiangling and the father of executive director Mr. Wang Lei, and the company reminded shareholders and investors to exercise caution when dealing in its securities.
On 11 September 2026, PAN ASIA ENVIRO (00556.HK) announced the disposal of a 51% equity interest in Xilailu Brand Management (Guangzhou) Co., Ltd. and the decision not to proceed with a proposed change of company name or the related extraordinary general meeting; the announcement stated that the group had not obtained management control over or participated in the daily operations of the target company as at 30 June 2026, that the buyer obtained no control over daily operations, key records, chops, licences, bank accounts or financial systems and did not participate in marketing or franchise activities, and that the target's results have not been and will not be consolidated, with the disposal having no material impact on the group's business.
On 11 September 2026, CHONG FAI JEWEL (08537.HK) announced that Ms. Fu Danling has resigned as an executive director with effect from 11 September 2026 due to the need to devote more time to her other personal affairs and business commitments, having confirmed that she has no disagreement with the board or the company and that no other matters relating to her resignation need to be brought to shareholders' or the Stock Exchange's attention; as at the announcement date, the executive directors are Mr. Fu Chun Keung, Ms. Cheung Lai Yuk and Mr. Fu Ho Hon.
On 11 September 2026, SITOY GROUP (01023.HK) issued a profit warning, expecting a loss attributable to owners of the Company of approximately HKD 110,000,000 to HKD 130,000,000 for the year ended 30 June 2026, narrower than approximately HKD 178,074,000 in 2025, mainly because the one-off significant loss from terminating the Cole Haan business did not recur and the fair value loss on investment properties fell to approximately HKD 50,000,000 to HKD 55,000,000.
On 11 September 2026, DIAGENS-B (02526.HK) announced that it has entered into a three-year cooperation framework agreement with Zhejiang Anzhen'er Medical Artificial Intelligence Technology Co., Ltd. covering medical imaging artificial intelligence, primary-level imaging cloud services and medical data products, with the parties intending to jointly build a Zhejiang provincial cloud platform for AI-assisted medical imaging diagnosis. No specific agreements have been entered into for specific cooperation projects.
on September 11, 2026, the three major Hong Kong indices opened lower and fluctuated, with the Hang Seng Index down 0.60%, the Hang Seng TECH Index down 0.23%, and the Hang Seng China Enterprises Index down 0.34%. The Hang Seng Index's full-day total market turnover was 228.4 billion HKD, Southbound funds saw a net inflow of 4.431 billion HKD.
On 11 September 2026, HANSOH PHARMA (03692.HK) announced that Ruikang Lifutuota Monoclonal Antibody for injection (HS-20093) has been included in the NMPA priority review and approval procedure for small cell lung cancer that has failed platinum-containing treatment, based on positive results from the pivotal Phase III trial ARTEMIS-008, with the inclusion dated 21 August 2026.
On 11 September 2026, UCD (01599.HK) announced that it submitted a filing application to the CSRC on the same day to convert an aggregate of 68,816,000 domestic unlisted shares into H shares under the proposed H-share full circulation. The conversion and listing remain subject to completion of the filing requirements and the obtaining of relevant approvals, and no application has yet been made to the Stock Exchange.
On 11 September 2026, CHOW TAI FOOK (01929.HK) announced that it has applied to NAFMII for registration of panda bonds of not more than RMB 10 billion, to be issued in multiple tranches within two years from receipt of the notice of acceptance of registration. This is the Company's first panda bond application, with proceeds intended for working capital and repayment of existing borrowings.
on September 11, 2026, the AI chip theme saw a volatile pullback, with SMIC (00981.HK) weakening. As of 13:46, the company was quoted at HK$62.950, down 0.79%.
on September 11, 2026, the humanoid robot theme saw a volatile pullback, with UBTECH ROBOTICS (09880.HK) weakening. As of 13:35, the company was quoted at HK$77.200, down 4.22%.
On 11 September 2026, YEEBO (INT'L H) (00259.HK) announced that Suzhou Qingyue Optoelectronics Technology, formerly listed on the SSE STAR Market, has triggered a mandatory delisting scenario for trading-related reasons after its daily closing price fell below RMB 1 for 20 consecutive trading days, with trading suspended on the SSE from 11 September 2026 and delisting possible; Suzhou Qingyue must engage a qualified sponsoring broker to transfer its shares to the NEEQ or other venues so trading can resume within 45 trading days of formal delisting, while the group's investment carrying amount was approximately HKD 161,000,000 as at 31 March 2026, or 2.28% of total assets and 2.85% of total equity.
GENSCRIPT BIO (01548.HK) plans to issue in total 77.13 million shares by placement, with estimated net proceeds of HKD 2.33 billion.
On 11 September 2026, DMALL (02586.HK) announced that controlling shareholder Dr. Zhang Wenzhong bought 1,361,400 ordinary shares on the open market for the first time on 10 September through Celestial Limited with his own funds, saying the price does not reflect the company's intrinsic value, and he intends to increase his holding further at an appropriate time.
